News

 

Sanderson McLeod hires Chief Scientific Officer for Heat Biologics

DURHAM, N.C., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a leader in the development of immunotherapies designed to activate a patient’s immune system against cancer, announced the appointment of Jeff Hutchins, Ph.D., as Chief Scientific Officer and Senior Vice President of Preclinical Development. Dr. Hutchins will be overseeing Heat’s research efforts, bringing over 24 years of research and clinical development experience from both large pharmaceutical and biotechnology companies more

Arch Therapeutics meets primary and secondary endpoints in first clinical study

FRAMINGHAM, MA -- (Marketwired) -- 08/15/16 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of devices for use in controlling bleeding and fluid loss in order to provide faster and safer surgical and interventional care, successfully met the objectives of its recently completed single-center, randomized, single-blind prospective clinical study (NCT 02704104) of the AC5 Topical Hemostatic Device in skin lesion patients with bleeding wounds. This was the first study assessing the safety and performance of AC5 in human more

Fractyl reports postive data for intestinal resurfacing to treat diabetes

While multiple diabetes associations have recommended bariatric surgery as a standard treatment for some diabetics, it's still unsuitable for the mass treatment of patients. Enter Fractyl Labs, which just reported data from the first-in-human study of its endoscopic duodenal mucosal resurfacing treatment more

Flagship creates a CMO role for their venture firm

Flagship Ventures has created a new spot for former Merck EVP and CMO Dr. Michael Rosenblatt, benefiting from the R&D reorg at the pharma. He is joining the venture firm as CMO. Flagship is creating the position with Rosenblatt's hire. more

Gemphire goes public

August 4, 2016 - Gemphire Therapeutics managed to get its IPO out in the dog days of summer. But it languished several weeks and then had to cut its pricing expectations. The company expects to use the $30 million it has raised for late-stage testing of its gemcabene in a trio of dyslipidemia disorders. more

 

Medtronic buys Heartware in 1.1 billion dollar deal

Medical device maker Medtronic said Monday it would buy HeartWare International, a company best known for its HVAD heart pump designed to help with heart failure for $1.1 billion. The mechanical pump requires less invasive surgery than other treatments for heart failure.more

Gemphire Therapeutics sets IPO for Thursday 6-23-2016

Northville-based Gemphire Therapeutics Inc., a cardiovascular drug development company, is scheduled to have its initial public offering on the Nasdaq Stock Exchange on Thursday, according to a posting on the Nasdaq website Monday. more

 

From Fierce Drug Delivery

Engineered proteins direct drugs to difficult tumors  Researchers at Stanford have developed a targeted approach to cancer treatment using not the usual antibodies but engineered proteins to direct drugs to a tumor. The proteins boast several advantages over antibodies, which can be fairly limited in their approach--one such advantage could be their ability to cross the blood-brain barrier and treat cancers there. more

Puma Biotechnology Presents Positive Phase II Data at the 2016 ASCO Annual Meeting LOS ANGELES, Calif., June 5, 2016

- Puma Biotechnology, Inc. (NYSE: PBYI), a biopharmaceutical company, presented positive results from an investigator sponsored Phase II trial of neratinib with HER2-mutated, non-amplified breast cancer. The data were presented today in a poster discussion session at the American Society of Clinical Oncology (ASCO) 2016 Annual Meeting in Chicago, Illinois. The poster (Abstract #516), entitled "Phase II Trial of Neratinib for HER2 Mutated, Non-Amplified Metastatic Breast Cancer (HER2mutMBC), was presented from 8:00-11:30 a.m. CDT today with a poster presentation discussion occurring immediately following the poster session.  more

HeartWare Completes Enrollment In HVAD® System LATERAL Study

FRAMINGHAM, Mass., April 27, 2016 /PRNewswire/ -- HeartWare International, Inc. (NASDAQ: HTWR), a leading innovator of less-invasive, miniaturized circulatory support technologies that are revolutionizing the treatment of advanced heart failure, today announced completion of enrollment in the HeartWare ® Ventricular Assist System (HVAD® System) LATERAL Study. more